38.9%), epidural abscess (38.9%), and bone/joint infections (33.3%). Opioid use disorders (OUD) were most common (94.4%), followed by cocaine (33.3%) and benzodiazepines (16.7%). All individuals completed the recommended course of IV antibiotics. All OUD patients received buprenorphine (52.9%) or methadone (47.1%). Two (11.1%) relapsed to drug use during OPAT, but no instances of line tampering, thrombosis, line infection or line dislodgement were identified. No deaths or overdoses were reported. Collectively, 504 inpatient days were avoided. Compared with 390 individuals without any history of IDU, those with IDU history were significantly younger (38.4 vs. 59.0, P < 0.0001), had fewer episodes of endocarditis (38.9% vs. 43.6%) and bone/joint infections (33.3% vs. 41.8%), but more epidural abscesses (38.9% vs. 3.1%). There were no statistical differences in rates of readmission (22.2% vs. 11.3%), line complications (0% vs. 3.5%), mortality (0% vs. 1.0%), ID clinic visit attendance (100.0% vs. 82.0%), or number of days on OPAT (28.0 vs. 30.1).
Background.
A patient-specific antibiogram (PS-ABG) issues personalized predicted antibiotic susceptibility results by incorporating patient factors into a prediction model. Predictions, reported as percent likelihood of susceptibility, are available to providers in real-time. In this study, we evaluated the performance characteristics of a PS-ABG based on a machine-learning algorithm in predicting susceptibility of Enterobacteriaceae isolated on urine cultures.
Methods.
This cross-sectional study included 2,517 urine cultures with Enterobacteriaceae collected from 2,211 unique patients over a 12-week period from January 1 through April 15, 2019 in a single health system. Receiver operating curves (ROC) were generated for commonly prescribed antibiotics to assess discrimination. Threshold values to determine when an antibiotic could be used were then determined based on ROC curves. Brier scores were generated for all antibiotics collectively and for individual antibiotics to evaluate the accuracy of the predictions compared with that of the usual practice (UP) of traditional antibiograms.
Results. The ability of the PS-ABG to discriminate susceptible and nonsusceptible isolates varied by antibiotic [area under the curve (AUC) range: 0.71 -0.95]. When all antibiotics were considered, AUC was 0.88 (95% C.I. 0.88 -0.89). Brier score ranged from 0.0037 -0.2087, representing between a 9 -56% improvement compared with UP. For all antibiotics, the software had a 32% improvement over UP (median Brier score 0.0794 v. 0.1114, P < 0.0001). Overall, a susceptibility threshold of 95% was associated with a specificity of 96%. A threshold of 95% was associated with a ≥90% specificity in all agents except for cefepime (specificity 70%) and meropenem (specificity 73%). For cefepime and meropenem, specificity reached 90% at a threshold of 97%.
Conclusion. The PS-ABG demonstrated excellent discriminatory power for all antibiotics tested and was more accurate than UP. A cutoff of 95% likelihood of susceptibility affords high specificity for most agents and may be a reasonable threshold for selecting an appropriate antibiotic. A higher susceptibility threshold yields similar specificity for cefepime and meropenem, but this finding is likely a result of the low number of resistant isolates.
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No reported disclosures. Background. Vancomycin may be administered via intermittent infusion (I-I) or continuous infusion (C-I). C-I vancomycin has advantages including the potential for less nephrotoxicity; however, available data are inconsistent and varies based on inpatient and outpatient settings. Thus, the primary objective of this study was to compare rates of nephrotoxicity in patients who received C-I or I-I vancomycin in an outpatient parenteral antimicrobial therapy (OPAT) program. Secondary objectives included time to onset of nephrotoxicity and clinical failure.
Comparison of Vancomycin Continuous and Intermittent Infusion Dosing Strategies Among Patients in an Outpatient Antimicrobial Therapy Program
Methods. This was a single-center, propensity score-matched, retrospective cohort study of patients who received C-I or I-I vancomycin for at least one week in the OPAT program between October 1, 2017 and March 31, 2019. Exclusion criteria included patients lost to follow-up, age less than 18 years old, and those requiring renal replacement therapy. Nephrotoxicity was defined as a serum creatinine (Scr) increase of >0.5 mg/dL or >50% from baseline for two consecutive measurements. Clinical failure was defined as unplanned readmission, extension of planned therapy, or change in antibiotic therapy.
Results. Three hundred patients were identified who received C-I or I-I vancomycin. After propensity score matching and exclusion criteria were applied, 74 patients were included in each cohort. Demographic information was similar between cohorts including baseline Scr, age, gender, comorbidities, concurrent nephrotoxins, indication, and vancomycin duration. C-I was associated with a 3.22-fold decrease in nephrotoxicity risk when compared with I-I [C-I: 6.8% vs. I-I 18.9%; OR (95% CI): 3.22 (1.10-9.46), P =0.027]. C-I was associated with a significantly slower onset to nephrotoxicity compared with I-I (P = 0.035; Figure 1 ). A significant difference in clinical failure was not observed between C-I and I-I (10/74, 13.7% vs. 17/74, 23.0%; P = 0.147).
Conclusion. C-I vancomycin was associated with a lower nephrotoxicity risk and slower onset to nephrotoxicity, but no difference in clinical failure rates when compared with I-I.
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